Trial Profile
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PerFECT
- 31 Jan 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Mar 2020.
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2017 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.